The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody
-
摘要: 炎症性肠病是一组病因尚不十分明确的慢性非特异性肠道炎症性疾病, 包括溃疡性结肠炎和克罗恩病, 以抗肿瘤坏死因子α单克隆抗体为代表的生物制剂在炎症性肠病中主要用于治疗克罗恩病。《抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)》在本期发布, 通过再读新版共识, 重点探讨抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的部分关键问题, 以帮助临床医生提高认识。
-
关键词:
- 抗肿瘤坏死因子α单克隆抗体 /
- 克罗恩病
Abstract: Inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, are chronic nonspecific inflammatory diseases of bowels whose etiology is not clear. Anti-tumor necrosis factor(TNF)-α monoclonal antibody is one of the representative biological agents used for the treatment of Crohn's disease. The "2017 revised Consensus on the Anti-TNF-α Monoclonal Antibody Therapy of Inflammatory Bowel Disease" will be published in current issue. From reviewing the new consensus, the author discussed some key points of anti-TNF-α monoclonal antibody therapy in Crohn's disease, hoping to improve clinical practice of anti-TNF-α monoclonal antibody therapy in Crohn's disease. -
[1] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial[J].Lancet, 2002,359:1541-1549. doi: 10.1016/S0140-6736(02)08512-4 [2] Sands BE,Anderson FH, Bernstein CN,et al. Infliximab maintenance therapy for fistulizing Crohn's disease[J].N Engl J Med,2004,350:876-885. doi: 10.1056/NEJMoa030815 [3] Bouguen G, Siproudhis L, Gizard E,et al. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab[J].Clin Gastroenterol Hepatol,2013,11:975-981. doi: 10.1016/j.cgh.2012.12.042 [4] Singh S, AI-Darmaki A,Frolkis AD,et al.Postoperative mortality among patients with inflammatory bowel diseases:a systematic review and meta-analysis of population-based studies[J].Gastroenterology,2015,149:928-937. doi: 10.1053/j.gastro.2015.06.001 [5] Amiot A, Setakhr V, Seksik P, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy:a cohort study from the GETAID[J]. Am J Gastroenterol,2014,109:1443-1449. doi: 10.1038/ajg.2014.183 [6] Colombel JF, Sandborn WJ, Reinisch W,et al. Infliximab, azathioprine,or combination therapy for Crohn's disease[J]. N Engl J Med,2010,362:1383-1395. doi: 10.1056/NEJMoa0904492 [7] Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial[J].Gut,2014,63:88-95. doi: 10.1136/gutjnl-2013-304984 [8] Waugh AW,Garg S,Matic K,et al.Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab:long-term follow-up of a single centre cohort[J].Aliment pharmacol Ther,2010,32:1129-1134. doi: 10.1111/j.1365-2036.2010.04446.x [9] D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization:when to start, when to stop, which drug to choose, and how to predict response?[J]. Am J Gastroenterol,2011,106:199-212. doi: 10.1038/ajg.2010.392
点击查看大图
计量
- 文章访问数: 70
- HTML全文浏览量: 22
- PDF下载量: 9
- 被引次数: 0